These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27601279)

  • 1. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
    Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
    Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
    Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Tanabe K
    Target Oncol; 2018 Dec; 13(6):745-755. PubMed ID: 30328067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS; Ogan K; Master VA
    Cancer; 2022 Jun; 128(11):2073-2084. PubMed ID: 35285950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study.
    Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
    Clin Genitourin Cancer; 2017 Oct; 15(5):598-604. PubMed ID: 28495053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.
    Auclin E; Bourillon C; De Maio E; By MA; Seddik S; Fournier L; Auvray M; Dautruche A; Vano YA; Thibault C; Joly F; Brunereau L; Gomez-Roca C; Chevreau C; Elaidi R; Oudard S
    Clin Genitourin Cancer; 2017 Jun; 15(3):350-355. PubMed ID: 28216276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy.
    Nicaise EH; Schmeusser BN; Ali A; Midenberg E; Palacios AR; Hartsoe B; Kearns E; Ambadi S; Patil DH; Joshi SS; Narayan VM; Psutka SP; Nazha B; Brown JT; Ogan K; Bilen MA; Master VA
    Clin Genitourin Cancer; 2024 Jun; 22(3):102056. PubMed ID: 38443295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
    Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
    Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
    Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
    World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy.
    Kalogirou C; Mulfinger P; Sokolakis I; Krebs M; Kübler H; Riedmiller H; Vergho D
    Urol Int; 2017; 99(3):297-307. PubMed ID: 28624829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis.
    Blute ML; Ziemlewicz TJ; Lang JM; Kyriakopoulos C; Jarrard DF; Downs TM; Grimes M; Shi F; Mann MA; Abel EJ
    Urology; 2017 Feb; 100():139-144. PubMed ID: 27667156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.